Targeting platelet-derived growth factor receptor β inhibits the proliferation and motility of human pterygial fibroblasts

Mai, Weiqian; Chen, Minfeng; Huang, Maohua; Zhong, Jincheng; Chen, Jian; Liu, Xiaoyong; Deng, Juan; Yang, Xiaoxi; Ye, Wen‐Cai; Zhang, Rijia; Zhou, Qing; Zhang, Dongmei

doi:10.1080/14728222.2019.1653281

Cited by 6 publications

(5 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…82 Several studies have shown that in the natural history of pterygium formation and recurrence, expression of basic fibroblast growth factor, VEGF, transforming growth factor-β, and platelet-derived growth factor are increased. 24 83 84 Before 2009, medical adjunctive approaches to prevent neovascularization and future recurrence of pterygium included therapy with beta radiation, MMC, 5-FU, and corticosteroids in routine practice. 2 8 15 However, later, the value of anti-VEGFs was noticed by some authors, as these class of adjunct medications did not have significant ocular side effects like MMC or 5-FU.…”

Section: R Esultsmentioning

confidence: 99%

Recurrent pterygium: A review

et al. 2021

View full text Add to dashboard Cite

Purpose: To summarize the recent evidence regarding different aspects of pterygium recurrence. Methods: Human-based studies from PubMed, Scopus, and Google Scholar were identified using the following keywords: conjunctival disease, pterygium, recurrent pterygium, pterygium recurrence, pterygium management/surgery, conjunctival autograft (CAU), amniotic membrane graft/transplant, and adjuvant therapy (January 2009 to February 2021). We reviewed risk factors associated with the recurrence of pterygium, timing of recurrence, medical treatments to prevent from recurrence, and nonsurgical and surgical alternatives for management of recurrence. Results: Dry eye disease, black race, and young age are considered definite risk factors for recurrence. However, fleshy appearance of the pterygium and preoperative size remain controversial. Surgical techniques such as excessive suturing, insufficient conjunctival graft size, thick conjunctival graft with remained Tenon tissue, and postoperative graft retraction are considered possible risk factors for recurrence. Using fibrin glue instead of sutures can further reduce recurrence rates. Although recurrence could occur even after many years, most recurrences happen in the first 3–6 months after surgery. Multiple kinds of adjuvant medications are used before, during, or after the operation including mitomycin C (MMC), 5-ﬂuorouracil (5-FU), corticosteroids, and anti-vascular endothelial growth factors (anti-VEGFs). Multiple weekly subconjunctival 5-FU injections are shown to be safe and effective in halting the progression of recurrent pterygium. Although topical bevacizumab is found to inhibit the growth of impending recurrent pterygium, the effect is mostly temporary. CAU is superior to amniotic membrane transplantation in the treatment for recurrent pterygia. Conclusions: There is yet to be a panacea in treating recurrent pterygium. Currently, there is not a globally accepted recommendation for treating recurrent pterygium with anti-VEGFs or 5-FU as a nonsurgical treatment. We strongly recommend using MMC as an adjunct to surgery in recurrent cases, with consideration of its specific complications. CAU is the most effective surgical treatment for recurrent pterygium, and other new surgical therapies need further investigation.

show abstract

Section: R Esultsmentioning

confidence: 99%

Recurrent pterygium: A review

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Looking ahead, the focus in pterygium research is on identifying genetic and molecular factors that contribute to the risk of recurrence, with the goal of developing medical therapies. Research has found abnormal expression of platelet-derived growth factor receptor β (PDGFR-β) in the stroma of pterygium, suggesting that its inhibitor, sunitinib, could, potentially, be used as a treatment [ 60 ].…”

Section: Corneal Limbusmentioning

confidence: 99%

Ocular-Surface Regeneration Therapies for Eye Disorders: The State of the Art

Posarelli

Romano

Tucci

et al. 2023

BioTech

View full text Add to dashboard Cite

The ocular surface is a complex structure that includes cornea, conjunctiva, limbus, and tear film, and is critical for maintaining visual function. When the ocular-surface integrity is altered by a disease, conventional therapies usually rely on topical drops or tissue replacement with more invasive procedures, such as corneal transplants. However, in the last years, regeneration therapies have emerged as a promising approach to repair the damaged ocular surface by stimulating cell proliferation and restoring the eye homeostasis and function. This article reviews the different strategies employed in ocular-surface regeneration, including cell-based therapies, growth-factor-based therapies, and tissue-engineering approaches. Dry eye and neurotrophic keratopathy diseases can be treated with nerve-growth factors to stimulate the limbal stem-cell proliferation and the corneal nerve regeneration, whereas conjunctival autograft or amniotic membrane are used in subjects with corneal limbus dysfunction, such as limbal stem-cell deficiency or pterygium. Further, new therapies are available for patients with corneal endothelium diseases to promote the expansion and migration of cells without the need of corneal keratoplasty. Finally, gene therapy is a promising new frontier of regeneration medicine that can modify the gene expression and, potentially, restore the corneal transparency by reducing fibrosis and neovascularization, as well as by stimulating stem-cell proliferation and tissue regeneration.

show abstract

“…The CRISPR/Cas9 system, as well as PDGFR-B siRNA and pCMV3-PDGFR-B plasmid, was used to identify PDGFR-β as a potential therapeutic target for pterygium (Mai et al, 2019). Lin et al established a thyroid cancer cell line with 95.6% PDGFRA gene insertion and deletions through CRISPR/Cas9, and demonstrated that xenograft distant lung metastasis was completely eliminated by PDGFRA gene editing; therefore, PDGFRA could be an effective target to inhibit distant metastasis in advanced thyroid carcinoma (Lin et al, 2021).…”

Section: Parkinson's Disease Treatment Based On Single-cell Transcrip...mentioning

confidence: 99%

Insights Into the Role of Platelet-Derived Growth Factors: Implications for Parkinson’s Disease Pathogenesis and Treatment

Huang

Zhang

et al. 2022

Front. Aging Neurosci.

View full text Add to dashboard Cite

Parkinson’s disease (PD), the second most common neurodegenerative disease after Alzheimer’s disease, commonly occurs in the elderly population, causing a significant medical and economic burden to the aging society worldwide. At present, there are few effective methods that achieve satisfactory clinical results in the treatment of PD. Platelet-derived growth factors (PDGFs) and platelet-derived growth factor receptors (PDGFRs) are important neurotrophic factors that are expressed in various cell types. Their unique structures allow for specific binding that can effectively regulate vital functions in the nervous system. In this review, we summarized the possible mechanisms by which PDGFs/PDGFRs regulate the occurrence and development of PD by affecting oxidative stress, mitochondrial function, protein folding and aggregation, Ca2+ homeostasis, and cell neuroinflammation. These modes of action mainly depend on the type and distribution of PDGFs in different nerve cells. We also summarized the possible clinical applications and prospects for PDGF in the treatment of PD, especially in genetic treatment. Recent advances have shown that PDGFs have contradictory roles within the central nervous system (CNS). Although they exert neuroprotective effects through multiple pathways, they are also associated with the disruption of the blood–brain barrier (BBB). Our recommendations based on our findings include further investigation of the contradictory neurotrophic and neurotoxic effects of the PDGFs acting on the CNS.

show abstract

Targeting platelet-derived growth factor receptor β inhibits the proliferation and motility of human pterygial fibroblasts

Cited by 6 publications

References 46 publications

Recurrent pterygium: A review

Recurrent pterygium: A review

Ocular-Surface Regeneration Therapies for Eye Disorders: The State of the Art

Insights Into the Role of Platelet-Derived Growth Factors: Implications for Parkinson’s Disease Pathogenesis and Treatment

Contact Info

Product

Resources

About